These innovative molecules represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://aliciapdld474843.blog-eye.com/39445801/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide